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Reducing the risk of stroke in elderly patients 
with non-valvular atrial fibrillation: a practical 
guide for clinicians
Joanne M Foody
Department of Medicine, Harvard 
Medical School, Boston, MA, USA
Abstract: Non-valvular atrial fibrillation (NVAF) significantly contributes to the burden of 
stroke, particularly in elderly patients. The challenge of optimizing anticoagulation therapy is 
balancing efficacy and bleeding risk, especially as the same patients at high risk of stroke also 
tend to be at high risk of bleeding. Treating the elderly patient with NVAF presents special 
challenges because of their heightened risk for both stroke and bleeding. Despite clinical trial 
data and evidence-based guidelines, surveys indicate that physicians underuse anticoagulation 
in older patients for reasons that include overemphasis of bleeding risk, particularly with the 
increased risk of falling, at the cost of thromboembolic risk. Clinical trial data are now avail-
able, and real-world data are emerging, to illustrate the relative merits of the non-vitamin K 
antagonist oral anticoagulants compared with conventional anticoagulation in the treatment 
of elderly patients with this condition, and to suggest some subgroups of older patients who 
may be more suitable candidates for particular agents. Care of elderly patients with NVAF 
is often complicated by factors including risk of falling, adherence, health literacy, cognitive 
function, adverse effects, and involvement of caregivers, as well as other factors including 
the patient–provider relationship and logistical barriers to obtaining medication. Thus, con-
versations between clinicians and patients, as well as shared decision making, are important. 
In addition, elderly patients often suffer from comorbidities including hypertension, coronary 
heart disease, diabetes mellitus, COPD, and/or heart failure, which necessitate the use of 
multiple concomitant medications, increasing the risk of drug/drug interactions. This review 
provides an overview of clinical trial data on the use of non-vitamin K anticoagulant agents 
in elderly populations, and serves as a practical resource for the management of NVAF in the 
elderly patient.
Keywords: aged, non-vitamin K antagonist oral anticoagulants, stroke, warfarin, bleeding
Introduction
The prevalence of atrial fibrillation (AF) in the US population (estimated at 5.2 million 
in 2010) is projected to increase to 12.1 million by 2030.1 While age-adjusted inci-
dence of clinically recognized AF has risen in recent decades, a 1993–2007 Medicare 
sample found a steady incidence, indicative of the association of AF with an aging 
population.2,3 AF, the most common cardiac arrhythmia, is a significant risk factor for 
stroke, increasing the risk fivefold.4,5
In analysis of trial data from ~9,000 patients with AF, increasing age was found to 
be associated with elevated stroke risk (hazard ratio [HR] per decade increase, 1.45; 
95% confidence interval [CI] 1.26–1.66).6 Elderly patients with AF also often suffer 
from impactful comorbidities, including hypertension, coronary heart disease, diabetes 
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mellitus, COPD, and/or heart failure; the kidney is particularly 
affected by aging, losing mass and glomerular and tubular 
function.2,7
Among Medicare beneficiaries with AF, the mean age is 
80 years, and 55% are female;2 a meta-analysis has demon-
strated women $75 years to be at an elevated risk of stroke 
vs men among patients with AF (relative risk [RR], 1.28; 95% 
CI 1.15–1.43).8 Female sex and increased age have both been 
identified as risk factors for stroke and incorporated into the 
CHA
2
DS
2
-VASc (Congestive heart failure, Hypertension, 
Age $75 years, Diabetes mellitus, Stroke, transient ischemic 
attack, Vascular disease, Age 65–74 years, Sex category) 
risk-scoring system, which includes, among other factors, 
1 point each for female sex and age 65–74 years, and 2 points 
for age $75 years.9 Table 1 shows factors included in both 
stroke risk and bleeding risk scores, highlighting the promi-
nence of advanced age in both.9–11 The American College 
of Cardiology provides tools on its website allowing users 
to calculate scores including CHA
2
DS
2
-VASc, HAS-BLED 
(Hypertension, Abnormal renal/liver function, Stroke, Bleed-
ing history, Labile international normalized ratio [INR], 
Elderly, Drugs/alcohol), and a combination of both.12
The challenge of optimizing anticoagulation therapy in all 
patients is balancing efficacy and bleeding risk, especially as 
the same patients at high risk of stroke also tend to be at high 
risk of bleeding.13 Vitamin K antagonists (VKAs), most nota-
bly warfarin, have been the standard of care for reducing the 
risk of stroke in patients with AF for over 50 years. Surveys 
have found physicians to be reluctant to prescribe warfarin 
for elderly patients, for reasons that include overemphasis of 
bleeding risk at the cost of thromboembolic risk, as well as 
the complications inherent to warfarin therapy (ie, drug/food 
and drug/drug interactions, need for frequent monitoring).14–16 
Four non-vitamin K antagonist oral anticoagulants 
Table 1 Risk scales for predicting stroke and risk of bleeding
Stroke risk Bleeding risk
CHADS2
10 CHA2DS2-VASc
9 HEMORR2HAGES
59 HAS-BLED11 ATRIA60
Age $75 years 
(1 point)
Age $75 years (2 points), 
age 65–74 years (1 point)
Age .75 years (1 point) Age .65 years (1 point) Age $75 years (2 points)
History of stroke 
or TIA (2 points)
Previous stroke/TIA/
thromboembolism (2 points)
Stroke (1 point) Stroke (previous history, 
particularly lacunar) (1 point)
Hypertension 
(1 point)
Hypertension (1 point) Hypertension (1 point) Hypertension (1 point) Hypertension (1 point)
CHF (1 point) CHF/left ventricular 
dysfunction (1 point)
Hepatic/renal disease  
(1 point)
Abnormal renal/liver function  
(1 point each)
Severe renal disease (eGFR 
,30 mL/min or dialysis-dependent) 
(3 points)
Diabetes mellitus 
(1 point)
Diabetes mellitus (1 point) Prior bleed (2 points) Bleeding history or predisposition 
(anemia) (1 point)
Any prior hemorrhage diagnosis 
(1 point)
vascular disease (prior 
myocardial infarction, 
peripheral artery disease, or 
aortic plaque) (1 point)
Anemia (1 point) Anemia (3 points)
Female sex (1 point) Reduced platelet count 
or function (1 point)
Labile INR (therapeutic time in 
range ,60%) (1 point)
Ethanol abuse (1 point) Drugs (antiplatelet agents, 
nonsteroidal anti-inflammatory 
drugs) or alcohol excess 
($8 units/week) (1 point each)
Malignancy (1 point)
Genetic factors (CYP2C9 
single-nucleotide 
polymorphisms) (1 point)
excessive fall risk (1 point)
Notes: Reprinted from Chest, 137(2), Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in 
atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. 263–272. Copyright 2010 with permission from Elsevier.9 Reprinted 
from Chest, 138(5), Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients 
with atrial fibrillation: the Euro Heart Survey. 1093–1100. Copyright 2010, with permission from Elsevier.11
Abbreviations: ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; CHA2DS2-vASc, Congestive heart failure, Hypertension, Age $75 years, Diabetes mellitus, 
Stroke, transient ischemic attack, Vascular disease, Age 65–74 years, Sex category; CHADS2, Congestive heart failure, Hypertension, Age $75 years, Diabetes mellitus, prior 
Stroke, TIA, or non-central nervous system thromboembolism doubled; CHF, congestive heart failure; eGFR, estimated glomerular filtration rate; HAS-BLED, Hypertension, 
Abnormal renal/liver function, Stroke, Bleeding history, Labile international normalized ratio, Elderly, Drugs/alcohol; HEMORR2HAGES, Hepatic or renal disease, Ethanol abuse, 
Malignancy, Older age, Reduced platelet count or function, Re-bleeding, Hypertension, Anemia, Genetic factors, Excessive fall risk, and Stroke; INR, international normalized ratio; 
TIA, transient ischemic attack.
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Stroke risk reduction in elderly NvAF patients
(NOACs) – the direct thrombin inhibitor dabigatran and 
the direct factor Xa inhibitors rivaroxaban, edoxaban, and 
apixaban – have been approved by the US Food and Drug 
Administration (FDA)17–20 for reducing the risk of stroke 
and systemic embolism (SE) in patients with non-valvular 
AF (NVAF). The aims of this review are to examine current 
and emerging data regarding the risks of stroke and bleeding 
in elderly patients with NVAF, to discuss the risk–benefit 
balance of various treatment options for NVAF in elderly 
patients, and to review the unique clinical challenges of 
managing NVAF in patients of advanced age.
Conventional therapy for elderly 
patients with NVAF
Numerous trials have shown the benefits of warfarin treat-
ment over placebo in patients with NVAF.21 Antiplatelet 
therapy has also been shown to reduce the risk of stroke in 
NVAF patients, albeit less effectively than anticoagulation 
and with less consistency among studies.21,22 Aspirin use 
continues to be prevalent in patients with AF, including older 
patients, as aspirin may be associated with lower bleeding 
risk vs warfarin.23,24 Physician surveys identify fear of bleed-
ing risk as the most commonly reported reason for not using 
anticoagulation in elderly patients.14
Despite physicians’ concerns, evidence suggests a gen-
erally positive balance of stroke risk and bleeding risk for 
warfarin in older patients. In 13,559 patients with NVAF 
(median age 73 years), patients aged $85 years were found to 
obtain particular benefit from VKA therapy, according to an 
analysis that accounted for both the rate of VKA-associated 
intracranial hemorrhage (ICH) and the rate of prevented isch-
emic strokes and systemic emboli. In patients aged $85 years 
receiving a VKA, the adjusted annual rate of thromboembo-
lism was 2.86 events per 100 patients lower and the adjusted 
annual rate of ICH was 0.35 events per 100 patients higher 
than those not receiving a VKA; corresponding rates for the 
entire cohort showed a reduction of 1.04% in thromboem-
bolism and a 0.24% increase in ICH.25
Clinical trial data: NOACs in 
patients with NVAF
In four Phase III trials, patients with NVAF at moder-
ate (CHADS
2
 [Congestive heart failure, Hypertension, 
Age $75 years, Diabetes mellitus, Prior Stroke, transient 
ischemic attack, or non-central nervous system thromboem-
bolism doubled] score $1) to high risk (CHADS
2
 score $2) 
of stroke were randomly assigned to receive NOAC or 
VKA treatment.26–29 Primary findings from each of the trials 
are summarized in Table 2. As there are no trials directly 
comparing the NOACs, and each trial enrolled different 
baseline populations and used different methodologies, care 
must be taken when making comparisons between agents.
A total of 18,113 patients (mean CHADS
2
 score 2.1; mean 
age 71 years) were randomized to dabigatran 110 or 150 mg 
or adjusted-dose warfarin in the Randomized Evaluation of 
Long Term Anticoagulant Therapy with Dabigatran (RE-LY) 
trial. In revised results from the intent-to-treat analysis, 
annual rates of stroke or SE in the dabigatran 150 mg group 
were superior vs warfarin (1.12% vs 1.72%; P,0.001), while 
rates in the dabigatran 110 mg group were comparable to war-
farin (1.54% vs 1.72%).26,30 In the Rivaroxaban Once-daily 
oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial 
in Atrial Fibrillation (ROCKET AF), 14,264 patients (mean 
CHADS
2
 score 3.5; mean age 73 years) were randomized 
to rivaroxaban 20 mg once daily (15 mg if creatinine clear-
ance [CrCl] was 30–49 mL/min) or warfarin. Rivaroxaban 
was noninferior to warfarin in the intent-to-treat analysis 
(annual rates of stroke/SE of 2.1% vs 2.4%; P,0.001 for 
noninferiority) and superior to warfarin in prespecified 
analyses of events during treatment (annual rates of 1.7% 
vs 2.2%; P=0.02).28 The Evaluation of Efficacy and Safety 
of Edoxaban versus Warfarin in Subjects with Atrial 
Fibrillation – Effective Anticoagulation with Factor Xa Next 
Generation in Atrial Fibrillation (ENGAGE AF-TIMI 48) 
trial randomized 21,105 patients with NVAF (mean CHADS
2
 
score 2.8; median age 72 years) to once-daily edoxaban 60 
or 30 mg (in either group, the dose was halved if any of the 
following applied: estimated CrCl 30–50 mL/min; body 
weight #60 kg; or concomitant use of verapamil, quinidine, 
or dronedarone) or VKA. Both edoxaban doses demonstrated 
noninferiority to VKA in reducing the risk of stroke or SE in 
the primary analysis, including patients in the intent-to-treat 
population who received study drug during the treatment 
period (annual rates of 1.61%, 1.18%, and 1.50% for low-
dose edoxaban, high-dose edoxaban, and warfarin, respec-
tively); high-dose edoxaban showed a trend toward better 
efficacy vs warfarin in a prespecified superiority analysis of 
the intent-to-treat population during the entire study period 
(1.57% vs 1.80%; P=0.08).29 In Apixaban for Reduction in 
Stroke and Other Thromboembolic Events in Atrial Fibrilla-
tion (ARISTOTLE), 18,201 patients (mean CHADS
2
 score 
2.1; median age 70 years) were randomized to apixaban 5 mg 
twice daily (2.5 mg doses were used in patients with two or 
more of the following: age $80 years, body weight #60 kg, 
or serum creatinine level $1.5 mg/dL) or warfarin. Apixaban 
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was superior to warfarin in the primary intent-to-treat analysis 
of the primary end point of stroke or SE (1.27% vs 1.60% 
annually; P=0.01).27
In RE-LY, dabigatran 110 mg reduced the risk of major 
bleeding vs VKA (2.92% vs 3.61% annually; P=0.003), 
while dabigatran 150 mg was associated with a similar rate 
of major bleeding vs VKA (3.40% vs 3.61%; P=0.41).26,30 
Whereas major bleeding was the primary end point in other 
Phase III studies of NOACs in patients with NVAF, the prin-
cipal safety end point in ROCKET AF was a composite of 
major and clinically relevant nonmajor bleeding; annual rates 
were 14.9% for rivaroxaban 20 mg and 14.5% for warfarin 
(P=0.44).28 Annualized rates of major bleeding specifically 
were 1.61%, 2.75%, and 3.43% for low-dose edoxaban, 
high-dose edoxaban, and warfarin, respectively (P,0.001 
for superiority for both edoxaban doses vs warfarin) in 
ENGAGE AF-TIMI 48.29 In ARISTOTLE, apixaban 5 mg 
was associated with reduced major bleeding vs warfarin 
(2.13% vs 3.09% annually; P,0.001).27
In an additional study, 5,599 patients with NVAF (mean 
CHADS
2
 score 2.1; mean age 70 years) who were unsuit-
able for VKA therapy were randomized to apixaban or 
aspirin. Apixaban was superior in reducing the risk of the 
primary outcome of stroke or SE (annual rates were 1.6% 
and 3.7% for apixaban and aspirin, respectively; P,0.001). 
The risk of major bleeding was similar between apixaban 
and aspirin (1.4% and 1.2% per year in the apixaban and 
aspirin groups, respectively).31
Figures 1 and 2 show rates of stroke/SE and major 
bleeding, respectively, in subgroups divided by age in the 
Phase III trials of NOACs for reducing the risk of stroke/SE 
in patients with NVAF. Table 3 shows more detailed efficacy 
and safety results from pivotal trials of NOACs examin-
ing reduction of stroke in NVAF in subgroups of patients 
aged $75 years.
In subgroups aged ,75 or $75 years from RE-LY, no 
interactions between age and treatment (dabigatran/warfarin) 
were evident for the outcome of stroke or SE. RRs in the 
aged ,75 years cohort were 0.93 (95% CI 0.70–1.22) for dab-
igatran 110 mg vs warfarin and 0.63 (95% CI 0.46–0.86) for 
dabigatran 150 mg vs warfarin; in patients aged $75 years, the 
respective RRs were 0.88 (95% CI 0.66–1.17) and 0.67 (95% 
CI 0.49–0.90). Additionally, both dabigatran 110 and 150 mg 
were associated with lower risks of major bleeding compared 
with warfarin in those aged ,75 years (RR, 0.62 [95% CI 
0.50–0.77] and 0.70 [95% CI 0.57–0.86] for dabigatran 110 
and 150 mg, respectively, vs warfarin). However, in the older 
subgroup, both doses of dabigatran were associated with more 
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Foody
Figure 1 Rates of stroke or systemic embolism by age subgroup in Phase III trials of NOACs in patients with NVAF.
Notes: values represent rates per 100 patient-years. Data from the following studies.27,29,31–33
Abbreviations: ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; AVERROES, Apixaban Versus Acetylsalicylic 
Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; CHADS2, Congestive heart failure, 
Hypertension, Age $75 years, Diabetes mellitus, prior Stroke, TIA, or non-central nervous system thromboembolism doubled; ENGAGE AF-TIMI 48, Evaluation of Efficacy 
and Safety of Edoxaban versus Warfarin in Subjects with Atrial Fibrillation – Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation; INR, international 
normalized ratio; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-valvular atrial fibrillation; RE-LY, Randomized Evaluation of Long-Term Anticoagulation 
Therapy; ROCKET AF, Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation; SE, systemic embolism; TIA, transient ischemic attack.
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Figure 2 Rates of major bleeding by age subgroup in Phase III trials of NOACs in patients with NVAF.
Notes: aP,0.05 for interaction between age and treatment. Values represent rates per 100 patient-years. Data from the following studies.27,29,31–33
Abbreviations: ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; AVERROES, Apixaban Versus Acetylsalicylic 
Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; CHADS2, Congestive heart failure, 
Hypertension, Age $75 years, Diabetes mellitus, prior Stroke, TIA, or non-central nervous system thromboembolism doubled; ENGAGE AF-TIMI 48, Evaluation of Efficacy 
and Safety of Edoxaban versus Warfarin in Subjects with Atrial Fibrillation – Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation; INR, international 
normalized ratio; NOAC, non-vitamin K antagonist oral anticoagulant; NVAF, non-valvular atrial fibrillation; RE-LY, Randomized Evaluation of Long-Term Anticoagulation 
Therapy; ROCKET AF, Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial 
Fibrillation; SE, systemic embolism; TIA, transient ischemic attack.
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Foody
gastrointestinal (GI) bleeding vs warfarin (RR, 1.39 [95% CI 
1.03–1.98] and 1.79 [95% CI 1.35–2.37] for dabigatran 110 
and 150 mg, respectively, vs warfarin).32 The US prescrib-
ing information for dabigatran (150/75 mg tablets) notes the 
elevated bleeding risk in geriatric patients.19
In the ROCKET AF subanalysis including 6,229 patients 
aged $75 years and 8,035 younger patients, rivaroxaban 
20 mg once daily (15 mg daily for those with moderately 
impaired renal function [CrCl 30–49 mL/min]) resulted 
in rates of stroke or SE and major bleeding similar to 
those with warfarin. In patients aged $75 years, the HR 
for rivaroxaban vs warfarin for stroke/SE was 0.80 (95% 
CI 0.63–1.02); in patients ,75 years of age, it was 0.95 
(95% CI 0.76–1.19; P=0.313 for interaction). The HR for 
major bleeding (rivaroxaban vs warfarin) in the $75 years 
subgroup was 1.11 (95% CI 0.92–1.34); in the younger 
subgroup, the HR was 0.96 (95% CI 0.78–1.19; P=0.336 
for interaction). Hemorrhagic stroke rates were similar in 
both age groups; there was no interaction between age and 
rivaroxaban response.33
No significant interaction was seen between treatment 
(edoxaban 30 mg vs warfarin or edoxaban 60 mg vs warfarin) 
and subgroups defined according to age ,75 or $75 years in 
subgroup analysis of ENGAGE AF-TIMI 48 for the primary 
efficacy end point of stroke or SE, or for the primary safety 
end point of major bleeding.29
In data from ARISTOTLE, no significant interaction 
by age category was observed for stroke/SE, all-cause 
mortality, major bleeding, all bleeding, ICH, or net clini-
cal effects for apixaban vs warfarin. The HR for stroke or 
SE (apixaban vs warfarin) was 1.16 (95% CI 0.77–1.73) 
in patients aged ,65 years, 0.72 (95% CI 0.54–0.96) in 
patients aged 65 to ,75 years, and 0.71 (95% CI 0.53–0.95) 
in patients aged $75 years; the respective HRs in these 
groups for major bleeding were 0.78 (95% CI 0.55–1.11), 
0.71 (95% CI 0.56–0.89), and 0.64 (95% CI 0.52–0.79).34 
Most patients who received the reduced 2.5 mg dose were 
$75 years; this dose was associated with reductions in 
stroke and major bleeding similar to those with the normal 
5 mg dose. Exploratory analysis found that age predicted 
major bleeding but was not associated with a differential 
treatment effect on major hemorrhage between warfarin 
and apixaban.35
In an analysis from Apixaban Versus Acetylsali-
cylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation 
Patients Who Have Failed or Are Unsuitable for Vitamin K 
Antagonist Treatment (AVERROES), apixaban was more 
efficacious than aspirin for reducing stroke risk in patients 
aged $75 years (HR 0.33) compared with patients T
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,75 years (HR, 0.68; P=0.06 for age interaction).36 No 
significant interaction with age was found for the risk of 
major bleeding.
A meta-analysis of data from trials of the NOACs dab-
igatran, rivaroxaban, and apixaban in patients with NVAF 
limited to those aged $75 years found a 35% reduction 
(odds ratio, 0.65; 95% CI 0.48–0.87) vs control (VKA in 
three studies, aspirin in one) in the risk of stroke or SE.37 
Pooled data from ten randomized controlled trials (includ-
ing trials for reducing stroke and SE in NVAF and trials in 
other thromboembolic disorders) showed no excess bleeding 
with NOACs vs conventional therapy (VKA or aspirin) in 
the $75-year population.
Recently, data have begun to emerge on the real-world 
use of NOACs in patients with NVAF. Two analyses have 
compared outcomes in Medicare beneficiaries receiving 
dabigatran vs those receiving warfarin. In a cohort of 134,414 
patients, dabigatran was associated with reduced risk of 
ischemic stroke (HR, 0.80; 95% CI 0.67–0.96; P=0.02), 
ICH (HR, 0.34; 95% CI 0.26–0.46; P,0.001), and overall 
mortality (HR, 0.86; 95% CI 0.77–0.96; P=0.006) but an 
increased risk of GI bleeding (HR, 1.28; 95% CI 1.14–1.44; 
P,0.001).38 The increase in GI bleeding risk appeared to 
be driven by the effects in women aged $75 years and men 
aged $85 years. In a group including 1,302 patients receiv-
ing dabigatran and 8,102 receiving warfarin, dabigatran 
was associated with a significantly higher risk of major and 
any bleeding than warfarin, after controlling for patient 
characteristics; the adjusted major bleeding incidence was 
9.0% (95% CI 7.8%–10.2%) for the dabigatran group and 
5.9% (95% CI 5.1%–6.6%) for the warfarin group. Addi-
tionally, patients receiving dabigatran had increased risk of 
GI bleeding (HR, 1.85; 95% CI 1.64–2.07) but decreased 
risk of ICH (HR, 0.32; 95% CI 0.20–0.50); the decrease in 
ICH associated with dabigatran was significant in patients 
older than 75 years (HR, 0.10; 95% CI 0.04–0.24) but not in 
younger patients.39 A retrospective analysis of administrative 
claims from a large database including privately insured and 
Medicare Advantage enrollees identified 92,816 new users of 
anticoagulants. In propensity score match models, the risk of 
GI bleeding in patients aged #75 years favored the NOACs 
over warfarin. In patients with NVAF aged .75 years, the 
risk of GI bleeding with dabigatran (n=2,063; HR, 2.49; 
95% CI 1.61–3.83 vs the reference warfarin 18–64 age 
group) exceeded the risk with warfarin (n=2,068; HR, 1.62; 
95% CI 1.02–2.58). Similarly, in patients with NVAF aged 
.75 years, the risk with rivaroxaban (n=1,582; HR, 2.91; 
95% CI 1.65–4.81) exceeded that with warfarin (n=1,609; 
HR, 2.05; 95% CI 1.17–3.59).40
Special clinical considerations in 
anticoagulation for the elderly 
patients with NVAF
Comorbidities
Additional factors complicating anticoagulation of elderly 
patients with NVAF include the frequent presence of multiple 
comorbidities. In a sample of almost 4 million patients 
hospitalized for AF (70% .65 years of age; 53% female), 
the most frequent comorbidities were hypertension (60%), 
diabetes mellitus (22%), and COPD (20%). Over the time 
observed (2000–2010), the comorbidity that most increased 
in prevalence was renal failure, which reached 12% by 
2010.41 Among patients with AF, the prevalence of chronic 
kidney disease (CKD) increases with age, and the addition 
of CKD as a comorbidity is associated with increased risk 
of stroke or SE and of bleeding. Patients with NVAF and 
renal disease have been found to be more likely to experi-
ence bleeding when treated with either warfarin or aspirin 
compared with those with NVAF only.42
NOAC metabolism is altered to varying degrees in 
patients with renal impairment, while renal clearance is con-
sidered to be a minor determinant of anticoagulant response 
to warfarin, and no warfarin dosage adjustment is necessary 
for patients with renal impairment.16 Patient characteristics 
related to renal and hepatic function and age may influence the 
choice of NOAC or warfarin use; the potential impact of these 
characteristics is outlined in Table 4.16–19,43 Elderly patients in 
general are subject to changes in kidney function, which leave 
them vulnerable to acute renal failure provoked by causes 
including dehydration, surgery, sepsis, and radiocontrast 
procedures.44 It should be noted that NVAF is associated not 
only with the impairment in renal function normally seen in 
aging patients but also with greater progression of kidney dis-
ease. In a cohort of 206,229 adults with CKD (mean age 70.7 
[standard deviation 11.0] years), incident AF was associated 
with a 67% higher relative rate of subsequent end-stage renal 
disease after adjustment for potential confounders.45
Interactions
The frequent presence of multiple comorbidities in elderly 
patients often necessitates multiple concomitant medications. 
In general, drug/drug interactions with NOACs are few com-
pared with potential interactions with warfarin;16 however, 
clinicians must be aware of a number of conflicts to avoid. 
Potential drug interactions of concern for patients taking 
dabigatran and edoxaban include other agents that affect 
the P-gp transport system.19,20 For apixaban and rivaroxaban, 
strong dual CYP3A4/P-gp inhibitors or inducers may have 
relevant potential for interaction.17,18
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Risk of falling
Significant predictors of not receiving warfarin in hospital-
ized patients aged $65 years with AF include increased 
age, cognitive impairment, history of hemorrhage, advanced 
malignancy, and history of falling. For patients $80 years 
of age, physicians cited risk of falling as the primary factor 
discouraging them from warfarin use.46 Retrospective analy-
sis of records from elderly patients with AF or atrial flutter 
who fell (42,913 on oral anticoagulation vs 334,960 controls) 
indicated a significantly higher mortality risk in those receiv-
ing anticoagulation (6% vs 3.1%; P,0.001). The increase in 
risk corresponded to a higher CHA
2
DS
2
-VASc score; patients 
with a score of 0–1 showed no additional mortality risk with 
anticoagulation, while patients with higher scores did show 
elevated risk.47 As age $75 years by itself receives 2 points 
in calculating CHA
2
DS
2
-VASc score,9 these results suggest 
that older patients with NVAF receiving anticoagulation may 
be at elevated mortality risk from falls. Indeed, preinjury 
warfarin use was seen to increase the odds of ICH by 40% 
and double 30-day mortality among Medicare beneficiaries 
with head trauma.48 Conversations between clinicians and 
patients and shared decision making are important in light 
of these data, which provide another factor to include in the 
difficult balance of risk and benefit in patients at the lower 
end of the stroke risk continuum.
Monitoring and adherence
Potential barriers to anticoagulation therapy adherence 
in elderly patients include the following: patient-related 
factors such as disease-related knowledge, health literacy, 
and cognitive function; drug-related factors such as adverse 
effects and polypharmacy; and other factors including the 
patient–provider relationship and various logistical barriers 
to obtaining medications.49 Warfarin is associated with the 
need for regular monitoring and dose adjustment to main-
tain treatment within the therapeutic range (INR 2.0–3.0),16 
and the INR testing at regular visits is used partially as a 
proxy for adherence to treatment. Although NOACs do not 
require monitoring,17–20 regular administration is particu-
larly important because of the quick onset/offset of action, 
making assessment of adherence an important component 
of follow-up visits. For patients with NVAF, the NOACs 
apixaban and dabigatran are to be taken twice daily, while 
rivaroxaban is administered once daily with the evening meal 
and edoxaban is taken once daily.17–20
Caregivers and coordination of care
Caregivers frequently play an essential participatory role 
in the care of elderly patients; .65 million people in the 
US provide this service, which for an elderly patient with 
NVAF may include confirming dosages, transporting to the 
primary care physician or anticoagulation clinic, and moni-
toring for signs of bleeding.50 Caregivers may play essential 
roles in the coordination of care, as elderly patients with 
NVAF (who frequently have multiple comorbidities) are 
treated by an interdisciplinary team. A caregiver may also 
be important in transitioning between providers, as when an 
elderly patient with NVAF must move from hospitalization to 
Table 4 Effect of non-modifiable patient characteristics on oral anticoagulant use
Characteristic Dabigatran19 Rivaroxaban17 Edoxaban20 Apixaban18 Warfarin16
Renal 
impairment
Dosing recommendations 
cannot be provided for those 
with CrCl ,15 mL/min or 
on dialysis
Use reduced dose  
(15 mg qd) in patients with 
CrCl 15–50 mL/min
Reduce dose to 
30 mg qd if CrCl 
15–50 mL/min
Reduce dose to 2.5 mg bid if 
two or more of the following 
were met: age $80 years, 
body weight #60 kg, serum 
creatinine $1.5 mg/dL
No dose 
adjustment 
required
Use reduced dose  
(75 mg bid) in patients with 
CrCl 15–30 mL/min
Not recommended if 
CrCl ,15 mL/min
Hepatic 
impairment
Administration in patients 
with moderate hepatic 
impairment showed large 
inter-subject variability but 
no evidence of consistent 
change in exposure
Avoid use in patients with 
Child–Pugh B and C hepatic 
impairment or any degree 
of hepatic disease associated 
with coagulopathy
Not recommended 
in patients with 
moderate or severe 
hepatic impairment
Not recommended in 
patients with severe hepatic 
impairment
Caution needed 
in patients with 
moderate-to-
severe hepatic 
impairment
Dosing recommendation 
cannot be provided in 
patients with moderate 
hepatic impairment
Age Risk of stroke and bleeding 
increases with age, but risk–
benefit profile is favorable in 
all age groups
Risk of stroke and bleeding 
increases with age, but risk–
benefit profile is favorable in 
all age groups
Efficacy and safety 
are similar in elderly 
and younger patients
Reduce dose to 2.5 mg bid if 
two or more of the following 
were met: age $80 years, 
body weight #60 kg, serum 
creatinine $1.5 mg/dL
Consider lower 
initiation and 
maintenance doses 
of warfarin in 
patients $60 years
Abbreviations: bid, twice daily; CrCl, creatinine clearance; qd, once daily.
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long-term care, requiring an accurate and complete exchange 
of information.51
Shared decision making
In addition to balancing stroke/SE and bleeding risks and 
taking into account special considerations for the elderly 
(including risk of falls), the recent introduction of NOACs 
allows individual preferences regarding convenience to be 
considered in selecting an anticoagulant regimen for each 
patient. The 2014 American Heart Association/American 
College of Cardiology/Heart Rhythm Society guidelines rec-
ommend that antithrombotic therapy should be individualized 
for patients with NVAF based on shared decision making 
after discussion about the absolute risks and RRs of stroke 
and bleeding and the patient’s values and preferences.52
emergent reversal
Abundant data testify to the association of advanced age with 
bleeding risk, which indicates the potential importance of 
reversal of anticoagulant effect in elderly patients. Although 
the short half-life of NOACs may decrease the need for 
immediate reversal, in cases of urgent bleeding or overdose 
of factor Xa inhibitor, no antidote is readily available, whereas 
idarucizumab has recently been approved for the reversal of 
dabigatran,53–55 and the activity of warfarin can be reversed 
by administration of vitamin K.16–20 Idarucizumab is a human-
ized monoclonal antibody fragment indicated in dabigatran-
treated patients when reversal of the anticoagulant effects 
of dabigatran is needed for emergency surgery or urgent 
procedures and for life-threatening or uncontrolled bleeding.55 
Idarucizumab received accelerated approval based on a reduc-
tion in unbound dabigatran and normalization of coagula-
tion parameters in healthy volunteers. However, continued 
approval for this indication may be contingent upon the results 
of an ongoing cohort case series study.55 A recombinant pro-
tein for the reversal of factor Xa inhibitors56 and a small syn-
thetic molecule for the reversal of all the NOACs are currently 
in development; idarucizumab is the only antidote that has yet 
received FDA approval.57,58 Procoagulant reversal agents such 
as prothrombin complex concentrate (PCC), activated PCC, 
and recombinant factor VIIa, although not evaluated in clinical 
trials, may be considered for reversal of apixaban; activated 
PCC, recombinant factor VIIa, and/or concentrates of coagu-
lation factors II, IX, or X may be considered for reversal of 
dabigatran but have not been evaluated in clinical trials; and 
PCC has partially reversed rivaroxaban-induced prothrombin 
time prolongation in healthy volunteers.17–19 Additionally, 
activated charcoal reduces absorption of apixaban, and 
dabigatran may be removed by hemodialysis, although there 
is no clinical evidence supporting these strategies in response 
to emergent bleeding.18,19
Conclusion
Treating the elderly patients with NVAF presents special 
challenges for many reasons, including, at the most 
fundamental level, their heightened risk for both stroke 
and bleeding. Despite clinical trial data and evidence-based 
guidelines, surveys indicate that many clinicians continue 
to underuse anticoagulation in those elderly patients who 
could receive benefit from it. Although clinical experience 
with the NOACs is relatively limited vs the familiar char-
acteristics of warfarin, subgroup analyses are now available 
to illustrate the relative merits of the new agents compared 
with standard anticoagulation in the treatment of elderly 
patients with NVAF.
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